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Hepatitis C virus is a leading cause of chronic hepatitis and liver cancer. Little information exists on the
interplay between innate defense mechanisms and viral antagonists that promote viral egress. Herein,
the effects of Tetherin/BST-2 on HCV release were investigated. In Huh-7.5 hepatocytes, low expression
levels of BST-2 were detected. Treatment of Huh-7.5 cells with IFNa, elevated BST-2 expression levels.
However, HCV could not alter the expression of IFNa-induced BST-2, nor of stably over-expressed BST-2.
Signiﬁcantly, over expressed BST-2 moderately blocked HCV production and release from Huh-7.5 cells.
Functional analysis of BST-2, conﬁrmed its ability to inhibit the release of HIV delta-Vpu from Huh-7.5-
BST-2 cells. HIV-Vpu antagonized BST-2 activity and rescued HIV delta-Vpu release from Huh-7.5-BST-2
cells. However, vpu slightly rescued HCV release and production from Huh-7.5-BST-2. We conclude that
BST-2 moderately restricts HCV production and release from Huh-7.5 hepatocytes, while the virus lacks
mechanisms to counteract this restriction.
& 2012 Elsevier Inc. All rights reserved.Introduction
Hepatitis C virus (HCV) is a leading cause of chronic hepatitis,
cirrhosis, and liver cancer worldwide. It is a major public health
problem, persistently infecting nearly 200 million people world-
wide. A vaccine against HCV is yet to be developed and current
anti-viral therapy is based on pegylated interferon a (IFNa) in
combination with ribavirin, which results in only limited sus-
tained virological response and severe side effects (Moradpour
et al., 2007; Wasley and Alter, 2000; Williams, 2006).
HCV is a 9.6 kb positive single-stranded RNA that replicates
primarily in hepatocytes (Choo et al., 1989; Kolykhalov et al.,
1997; Poynard et al., 2003). The viral genome is translated to a
single polyprotein of 3000 residues that is processed by host and
viral proteases into structural and non-structural (NS) proteins
(Appel et al., 2006; Bartenschlager et al., 2004; Lindenbach and
Rice, 2005; Murray et al., 2008). Efﬁcient systems to propagate
HCV in culture have been recently developed and helped to
characterize the different steps of HCV life cycle and to identify
host proteins that support these steps (Lindenbach et al., 2005).
Several host receptors and cofactors involved in viral entry and
receptor-mediated clathrin endocytosis were identiﬁed (Bartoschll rights reserved.et al., 2003a; Bartosch et al., 2003b; Blanchard et al., 2006; Codran
et al., 2006; Evans et al., 2007; Ploss and Rice, 2009; Randall et al.,
2007). HCV replication occurs on endoplasmic reticulum (ER)
associated membranous web structures (Egger et al., 2002; Gosert
et al., 2003; Moradpour et al., 2003), and viral RNA in complex
with viral and cellular proteins are then transferred to lipid
droplets (LD), where viral assembly takes place (Bartenschlager
et al., 2011; Counihan et al., 2011; Miyanari et al., 2007). In this
step, NS proteins, including p7, NS2, NS3, and NS5A are impor-
tant. Late events of HCV release are less clear (He et al., 2007;
Ng et al., 2007; Randall et al., 2007; Tai et al., 2009). Flavi-
viruses egress is thought to occur via secretory pathways and HCV
may utilize similar pathways to release from infected cells
(Lindenbach and Rice, 2003; Mackenzie and Westaway, 2011).
However, HCV is distinct as particles become infectious only after
acquiring the envelope and are secreted from cells in association
with distinct lipid and apolipoprotein via the secretory pathway-
from trans-Golgi Network (TGN) (Chang et al., 2007; Jiang and
Luo, 2009; Merz et al., 2011). Recent siRNA screens had identiﬁed
numerous host proteins of the secretory pathway that co-trafﬁc
with HCV core and are required for HCV release. Components of
ER to Golgi trafﬁcking (SAR1A), Golgi structure and function
(CYTH3), cargo sorting and vesicle budding from TGN (PRKD1,
AP1M1, PI4KB, CLINT1), regulators of TGN to plasma membrane
trafﬁcking (RAB11A, RAB3D, PACSIN3) and the v-snare, VAMP1
were all identiﬁed (Berger et al., 2009; Coller et al., 2009, 2012).
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is fundamental for completion of its replication cycle and estab-
lishing persistence. Viral RNA triggers innate antiviral response,
which leads to the synthesis of IFNa and IFNb. The virus activates
the RNA helicase retinoic acid inducible gene protein I [RIG-I],
which recognizes the foreign viral RNA. However, in contrast to
other RIG-I activating viruses, HCV is a poor IFN and pro-
inﬂammatory cytokine inducer. It mainly establishes chronic
infection due to the inefﬁciency of the host innate response to
antagonize viral evasion strategies. These include the activity of
NS3/4A protease that targets key components of the innate
response, the viral core protein that targets components of the
JAK/STAT pathways and E2/NS5A that bind to PKR and inhibit (in
some genotypes) its activation. NS5A also targets the antiviral
activity of oligoadenylate synthetase (2–5 OAS) (Taguchi et al.,
2004). Nevertheless, despite early disruption of the host innate
response, IFN type I stimulated gene expression (ISG) is elevated
during the ﬁrst 12 h of HCV infection, after which a rapid decline
at the protein level, rather than at the RNA level occurs. In
addition, microarray analysis of liver samples from HCV-infected
chimpanzees or chronically infected humans also show increased
ISGs expression, among them PKR; ISG56; ISG20; ADAR1 and
viperin are elevated in Bigger et al. (2004), Foy et al. (2005), Gale
and Foy (2005), Pezacki et al. (2009), Saito and Gale (2008),
Sarasin-Filipowicz et al. (2008), Sklan et al. (2009), Su et al. (2002)
and Sumpter et al. (2005).
Human BST-2/CD317/Tetherin is an IFN-type I induced, type II
glycosylated protein that is mainly localized to the surface plasma
membrane. It also associates with lipid rafts at the cell surface and
with internal membranes, presumably in the TGN (Andrew et al.,
2011; Dube et al., 2009; Hauser et al., 2010; Masuyama et al.,
2009). BST-2 was identiﬁed as a host restriction factor that disrupts
the release of vpu defective HIV particles. Nascent particles
assemble at the cell surface, but remain tethered to the infected
cell by BST-2 before being endocytosed and accumulated into late
endosomes. BST-2 disrupts the release of a broad spectrum of
viruses that either bud from cholesterol-enriched domains of
the plasma membrane (HIV and Ebola), or from the endoplasmic
reticulum and trans-Golgi network, followed by transport to the
cell surface in secretory vesicles (KSHV and Herpesvirus)
(Dietrich et al., 2011; Gofﬁnet et al., 2009, 2010; Groom et al.,
2010; Gupta et al., 2009; Lopez et al., 2010; Neil et al., 2007, 2008;
Perez-Caballero et al., 2009; Radoshitzky et al., 2010; Ruiz et al.,
2010; Van Damme et al., 2008; Van Damme and Guatelli, 2008;
Watanabe et al., 2011). To replicate in this hostile environment,
viruses have developed antagonists that counteract the restriction
of BST-2 and promote viral release. In HIV-1, the accessory protein
vpu interacts with BST-2 and accelerates viral release by down-
regulating surface expression of BST-2, targeting it to degradation.
Similarly, SIV Nef, KSHV K5 and HIV-2 GP also target BST-2 activity
(Douglas et al., 2010; Le Tortorec and Neil, 2009; Miyagi et al.,
2009; Pardieu et al., 2010; Sauter et al., 2009).
In this study we investigated the role of BST-2 in modulating
HCV replication at steps of viral production and release. Indeed,
microarray analyses that monitored the expression of BST-2 in HCV
infected cells are controversial, but some do demonstrate that BST-2
expression is modulated in vivo upon HCV infection (Bigger et al.,
2004; Pezacki et al., 2009; Sarasin-Filipowicz et al., 2008; Su et al.,
2002). Moreover, BST-2 expression levels are moderately high
in liver tissue (Erikson et al., 2011). HCV does not bud via the
membrane of infected cells, but is thought to replicate on detergent-
insoluble sub-cellular domains or lipid rafts membrane web struc-
tures, where BST-2 is expressed. Upon subjecting HCV infected cells
to membrane ﬂotation analysis, both viral NS proteins and RNA
were localized distinctively to these speciﬁc sub-domains (Gao et al.,
2004; Amemiya et al., 2008; Miyanari et al., 2007).Herein, only low basal expression levels of BST-2 were
detected in Huh-7.5 cells. HCV infection could not alter the low
basal expression levels of BST-2. Treatment of Huh-7.5 cells
with IFNa, induced expression levels of BST-2. However, IFNa-
mediated expression of BST-2 also was not modulated following
HCV infection. Similarly, expression levels of IFNa-induced BST-2
were not changed when cells were ﬁrst infected with HCV and
then treated with IFNa. As HCV cannot replicate in IFNa treated
cells, where BST-2 is induced, Huh-7.5-BST-2 stable cells were
generated by lentiviral transduction and sorting cells for high
BST-2 expression. In Huh-7.5-BST-2 cells, BST-2 expression levels
were also not down regulated upon HCV infection. Signiﬁcantly,
stably expressed BST-2 moderately blocked the release of HCV
from producing cells, as well as restricted HCV release and also
decreased cell associated viral particles from infected Huh-7.5
cells. Stably expressed BST-2 also inhibited the release of
HIV-delta Vpu from Huh-7.5-BST-2 cells, validating its function
as an inhibitor of HIV-delta vpu release from Huh-7.5 cells. Over
expression of vpu, rescued the release of HIV-delta Vpu virus from
Huh-7.5-BST-2 cells. Over expression of HIV vpu in Huh-7.5-BST-
2, only partially rescued the block in HCV release and production,
which was mediated by BST-2. We conclude that in vitro, BST-2
moderately modulates the replication of HCV at the steps of viral
production and release, while the virus lacks the mechanisms to
counteract this restriction. Furthermore, our study establishes a
possible role for human BST-2 in restricting late steps of HCV
particle release and highlights the continuous battle between
viral and host antiviral innate defense mechanisms.Results
BST-2 expression levels are low in HCV permissive Huh-7.5 cells and
are induced by IFNa
Huh-7.5 hepatocytes were initially analyzed for their basal
expression levels of BST-2. Cells were analyzed by FACS for BST-2
expression using an anti BST-2 polyclonal antibody, followed by
staining with a secondary anti-rabbit-Rhodamine Red-X conjugated
secondary antibody. Results show that Huh-7.5 cells expressed low
levels of BST-2 (Fig. 1A and B). Only 10% of Huh-7.5 cells positively
stained for BST-2, exhibiting relatively low MFI values of 564. As
BST-2 expression is induced by IFNa, Huh-7.5 cells were also treated
with increasing concentrations of IFNa. 24 h post-treatment, cells
were analyzed by FACS for BST-2 expression. Treatment of cells with
IFNa led to elevated expression levels of BST-2. Induction of BST-2
expression by IFNa was detected in both the percentage of cells that
were stained positively for BST-2 and in the MFI values obtained in
the FACS analysis and compared to those obtained for Huh-7.5 non-
treated cells (Fig. 1A and B). Fig. 1B left panel represents FACS analysis
for BST-2 expression in Huh-7.5 cells and the right panel, represents
BST-2 expression in Huh-7.5 cells that were treated with 500 U/ml
IFNa). As not all cells were equally induced by IFNa, these results
indicated that BST-2 expression levels were induced by IFNa at the
level of a given cell. Expression of BST-2 following IFNa treatment
was also analyzed bywestern blot. BST-2 expression levels in Huh-7.5
were non-detectable, while treatment of cells with 500 U/ml IFNa,
resulted in elevated BST-2 expression levels (Fig. 1C; lane 2). We
conclude that in HCV permissive Huh-7.5 cells, BST-2 expression
levels are low and are induced upon treatment with IFNa.
HCV cannot modulate the expression levels of basal or IFNa induced
BST-2
We then asked if HCV could modulate basal or IFNa-induced
expression levels of BST-2. Huh-7.5 cells were infected with
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Fig. 1. BST-2 expression levels are low in Huh-7.5 cells and are induced by IFNa. (A) IFNa induces the expression of BST-2: Huh-7.5 cells were seeded in a 6 well plate and the
next day were treated with IFNa at the indicated concentrations (250–1000 U/ml). Cells were harvested 24 h post IFNa treatment and analyzed by FACS for BST-2
expression (lanes 3–5; black bars). Non-treated Huh-7.5 cells were also stained for BST-2 to monitor basal levels of BST-2 expression (lane 2). As control, cells were also
stained with only the secondary anti rabbit antibody (lanes 1; white bar). FACS results are presented as Y Geomean (Mean Fluorescent Intensity—MFI) values and are
representative of average of triplicate experiments; error bars are the standard deviation of the means. (B) FACS analysis for BST-2 expression following treatment of cells with
IFNa: Huh-7.5 cells (non-treated; left panel) or Huh-7.5 cells that were treated for 24 h with IFNa (500 U/ml; right panel), were harvested and analyzed for BST-2
expression by FACS. Gated percentage of BST-2 expressing cells and Y geaomean values are also presented. (C) Western blot analysis of Huh-7.5 cells following treatment of
cells with IFNa7 Huh7.5 cells or cells that were treated with 500 U/ml of IFNa or (lanes 1 and 2, respectively) were subjected to SDS-PAGE followed by western blot analysis.
BST-2 expression was detected with anti rabbit HRP conjugated secondary antibody. Lower panel conﬁrmed equal protein levels that were loaded on the gels as detected
by western blot for b actin.
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which expressed a luciferase reporter gene (Lindenbach et al.,
2005). 48 h or 72 h post-infection cells were analyzed for endo-
genous BST-2 expression by FACS. Low BST-2 expression levels
were detected in Huh-7.5 cells that were not treated with IFNa.
Only 10% of the cells were stained positively for BST-2 and MFI
levels were also basal, conﬁrming the results obtained in Fig. 1
(Fig. 2A; white bar). Moreover, infection of Huh-7.5 cells with
RLuc-HCV did not alter the endogenous expression levels of BST-2
that remained at their basal levels 48 h and 72 h post-infection
(Fig. 2A; black bars; lanes 3 and 4). To verify HCV infection in this
experimental setting, infected cell were lysed and analyzed for
viral replication by monitoring their luciferase activity (Fig. 2B).
RLuc-HCV efﬁciently replicated in Huh-7.5 cells. We conclude
that HCV cannot modulate basal BST-2 expression in HCV infected
Huh 7.5 cells.
To test if HCV can modulate expression levels of IFNa-induced
BST-2, Huh-7.5 cells were ﬁrst treated with IFNa (1000 U/ml) to
induce BST-2 expression and 24 h later IFNa was washed away.Cells were then either infected with RLuc-HCV or remained non-
infected. At the indicated time points post-IFNa removal, cells
were harvested and BST-2 expression levels were analyzed
by western blot (Fig. 3A). In HCV non-infected Huh-7.5 cells
that were not treated with IFNa, BST-2 expression was not
detectable (Fig. 3A; lane 1). Treatment of cells with IFNa, induced
expression of BST-2, as detected 24 h post-removal of IFNa
(Fig. 3A; lane 2). BST-2 displayed typical migration patterns on
SDS-PAGE, reﬂecting differential N-glycosylation and dimer for-
mation. At later points (48 h and 72 h) post-IFNa removal, BST-2
expression levels in non-infected Huh-7.5 cells decreased. Expres-
sion of dimeric forms diminished and BST-2 levels reached basal
non-detectable levels at 72 h post-IFNa removal (Fig. 3A; lanes 3
and 4). Importantly, similar kinetics of reduction of BST-2 expres-
sion post-IFNa removal was observed in cells that were treated
with IFNa to induce BST-2 expression and then were infected
with RLuc-HCV (Fig. 3A; compare lanes 3–4 and 5–6). Levels of
b-actin validated that equal amounts of proteins were loaded
on the protein gel (lower panel). These results conﬁrmed that
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Fig. 2. HCV cannot modulate basal expression levels of BST-2 in Huh-7.5 cells. (A) Basal expression levels of BST-2 in HCV infected Huh-7.5 cells: Huh-7.5 cells were infected
with a monocistronic FL-J6/JFH-5.C19Rluc2AUbi (RLuc-HCV). At the indicated time points post-infection (48 and 72 h post-infection), cells were harvested and analyzed for
BST-2 expression by FACS. Error bars are the standard deviation of mean values obtained from triplicate experiments. (B) HCV replication in Huh-7.5 cells: RLuc-HCV
replication was conﬁrmed in cells that were analyzed for BST-2 expression in panel A. Infected Huh-7.5 cells were lysed and their renilla-luciferase activity was monitored
at the indicated time points post-viral infection. Results are representative of the mean of triplicate wells; error bars show the standard deviation of the means.
Fig. 3. HCV cannot modulate the expression levels of IFNa-induced BST-2. (A) Effects of HCV on IFNa induced expression of BST-2: Huh-7.5 cells were initially treated with
1000 U/ml of IFNa. 24 h later, IFNa was removed and cells were either remained non-infected (lanes 2–4), or infected with RLuc-HCV (lanes 5–6). At the indicated time
points post-IFNa wash, cells were harvested and subjected to western blot analysis for the expression of BST-2. Lower panel conﬁrmed equal protein levels that were
loaded on the gel as detected by western blotting with an antibody against b actin. (B) HCV cannot replicate in Huh-7.5 cells treated with IFNa: Huh-7.5 cells were treated
with 1000 U/ml of IFNa (white bars) or remained non-treated (black bars). 24 h later cells were infected with RLuc-HCV. At the indicated time points post-infection, cells
were harvested and monitored for HCV replication based on their luciferase counts. Luciferase readings are presented relatively to the background counts in Huh-7.5 cells
that were not treated with IFNa (black bars). Results are representative of the mean values from triplicate wells; error bars show the standard deviation of the means.
(C) Analysis of IFNa-induced BST-2 expression levels following initial HCV infection: Huh-7.5 cells were initially infected with RLuc-HCV (lane 2), or remained non-infected
(lane 1). 48 h post-infection, non-infected Huh-7.5 cells (lane 3) and HCV infected Huh-7.5 cells (lane 4) were subjected to IFNa treatment (1000 U/ml) to induce BST-2
expression. 48 h post-IFNa treatment, cells were harvested and analyzed by western blot for BST-2 expression, using a BST-2 polyclonal antibody. Lower panel conﬁrmed
equal protein levels that were loaded on the gel as detected by western blotting with an antibody against b actin.
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A. Dafa-Berger et al. / Virology 428 (2012) 98–111102HCV could not modulate BST-2 expression levels that were
induced by IFNa.
HCV replication was also monitored in Huh-7.5 cells that were
treated with 1000 U/ml IFNa (Fig. 3B; white bars) and compared
to cells that were not treated with IFNa (Fig. 3B; black bars). As
expected, HCV replication was substantially decreased in cells
that were treated with IFNa, emphesizing that HCV could not
modulate the expression of BST-2 that was induced by IFNa. We
conclude that the decrease in BST-2 expression levels following
removal of IFNawere not due to HCV ability to down-regulate the
expression of BST-2 (Fig. 3B).
BST-2 expression levels in Huh-7.5 cells were also monitored
by western blot upon initial infection of Huh-7.5 with RLuc-HCV.
48 h post-infection, BST-2 expression was induced by treatment
of infected cells with IFNa (1000 U/ml). 48 h post-IFNa treatment,
BST-2 expression in HCV infected cells was analyzed by western
blot (Fig. 3C). This experimental setting ﬁtted better to clinical
protocols which includes treatment with IFNa following HCV
infection. In HCV infected Huh-7.5 cells, BST-2 expression levels
were non-detectable and comparable to BST-2 basal levels
observed in non-infected cells (Fig. 3C; compare lanes 1 and 2).
Treatment of Huh-7.5 cells with IFNa, induced BST-2 expression
(Fig. 3C lane 3). Moreover, in cells that were ﬁrst infected with
HCV and 48 h later were treated with IFNa, BST-2 expression
levels remained high and comparable to BST-2 levels that were
detected in non-infected cells that were treated with IFNa
(compare lanes 3 and 4). These results conﬁrmed that initial
HCV infection also could not modulate IFNa-induced BST-2
expression.
HCV cannot modulate the expression levels of stably expressed BST-2
Since in Huh-7.5 cells BST-2 expression was only induced
following treatment of cells with IFNa, where HCV could not
replicate, Huh-7.5 cells that stably expressed BST-2 were gener-
ated using lentiviruses that promoted BST-2 expression under
the CMV promoter. The lentivector also coded for a puromycin
resistant gene that was expressed via an IRES sequence. Trans-
duced cells were selected on puromycin and were further sorted
based on their BST-2 expression to obtain cells that highly
expressed BST-2 (referred to as Huh-7.5-BST-2). Expression of
BST-2 in Huh-7.5-BST-2 stable cells was veriﬁed by FACS analysis.
98.8% of cells were stained positively for BST-2 and MFI values of
the FACS analysis were 1766, as compared to MFI of 564 Huh-7.5
expressing basal BST-2 expression (Fig. 4A; compare with Fig. 1B).
Western blot analysis of Huh-7.5-BST-2 conﬁrmed high levels of
BST-2 expression as compared to basal levels of BST-2 that were
not detectable in Huh-7.5 cells (Fig. 4B; compare lanes 1 and 2).
Furthermore, immunoﬂuorescence analysis (IFA) of Huh-7.5-BST-2
stable cells also veriﬁed high BST-2 expression in all cells, as
compared with Huh-7.5 cells, where BST-2 expression was almost
not detected (compare Fig. 4C; images a and b). BST-2 expression
in Huh-7.5-BST-2 stable cells was also detected intracellularly,
following permeabilization of Huh-7.5-BST-2 cells. Herein, BST-2
expression was also visualized in the cytoplasm (Fig. 4C; image c).
Bright-ﬁeld images corresponded to matched of the IFA images
(Fig. 4; Panels d–f).
To test if HCV could modulate the expression of stably-expressed
BST-2, Huh-7.5-BST-2 cells were infected with RLuc-HCV and at the
indicated time points (48 h and 72 h post-infection), cells were
harvested and analyzed by FACS for BST-2 expression (Fig. 5A).
BST-2 expression levels remained similar 48 h and 72 h post-
infection and were comparable with BST-2 expression levels in
non-infected Huh-7.5-BST-2 cells (Fig. 5A; compare gray bar with
black bars at lanes 3 and 4). MFI values of basal BST-2 expression in
Huh-7.5 were relatively low, conﬁrming the results that wereobtained in Fig. 1 (white bar). In Huh-7.5-BST-2, MFI values were
much higher. Overall, stable BST-2 expression levels were not
modulated in Huh7.5-BST-2 cells that were infected with HCV.
Western blot analysis also monitored the expression of BST-2
in Huh-7.5-BST-2 cells that either remained non-infected (Fig. 5B;
lanes 3–5), or were infected with RLuc-HCV (Fig. 5B; lanes 6–8).
Similar expression levels of BST-2 were detected at the indicated
time points in cells that were infected with HCV or remained non-
infected. (Fig. 5B; compare lanes 3–5 with lanes 6–8). Western
blot analysis for b-actin conﬁrmed equal amounts of protein that
were loaded on the gel (Fig. 5B; lower panel). Importantly, at the
same time points post-HCV infection, Huh-7.5 and Huh-7.5-BST-2
infected cells were monitored for their HCV replication (Fig. 5C).
HCV efﬁciently replicated in Huh-7.5 and in Huh-7.5-BST-2 stable
cells, implying that the virus lacks the mechanisms to modulate
BST-2 expression. Signiﬁcantly, replication efﬁciencies of RLuc
HCV were approximately 2-fold lower in Huh-7.5-BST-2 cells
(white bars) as compared to those detected in Huh-7.5 cells (black
bars; Fig. 5C). HCV infected Huh-7.5-BST-2 stable cells were also
analyzed for BST-2 and HCV-NS5A expression by FACS. As shown
in a representative dot-blot, 85% of cells were both infected with
HCV and expressed BST-2. IFA analysis was also performed on
Huh-7.5-BST-2 stable cells. Cells were stained for both BST-2 and
for HCV-NS5A. As shown, in HCV infected Huh-7.5-BST-2, BST-2
only moderately co-localized with HCV-NS5A (Fig. 5E; images a
and b).
BST-2 blocks viral release from HCV producing cells
Above results demonstrated that HCV could not modulate
BST-2 expression levels that were either induced by IFNa or stably
over expressed in Huh-7.5 cells. However, it remained to be
veriﬁed if over expressed BST-2 affects the production and release
of HCV (Fig. 6). Huh-7.5 that did not express BST-2 (closed circles)
or Huh-7.5-BST-2 stable cells (open circles) were electroporated
with RLuc-HCV RNA. At the indicated time points post-electro-
poration, cells were harvested and viral supernatants were col-
lected, clariﬁed and used for infectivity release assays of new Huh-
7.5 cells. 72 h post-infection, Huh-7.5 cells were harvested and
their viral-mediated luciferase activity was measured (Fig. 6A).
Moderately lower yields of HCV particles were released from Huh-
7.5 producing cells that stably expressed BST-2 (Fig. 6A; open
circles), when compared to viral particle release from HCV produ-
cing cells that did not express BST-2 (Fig. 6A; closed circles). At
early time points post-electroporation, viral release from Huh-7.5-
BST-2 stable cells exhibited a low rates of release compared to
HCV released from Huh-7.5 control cells that did not express
BST-2 (5 fold relative difference at 2 days post-electroporation). As
time point post-electroporation advanced, relative differences in
HCV release between the two cells types were stabilized around
2-fold in favor of the cells that did not express BST-2 (Fig. 6A).
Huh-7.5-BST-2 stable cells that were electroporated with HCV
RNA were also analyzed by FACS for BST-2 and for viral NS5A
expression (Fig. 6B). 89% of cells expressed both BST-2 and HCV
NS5A. We conclude that when over expressed, BST-2 moderately
restricts HCV release from Huh7.5 producing cells.
BST-2 restricts HCV particle production and release from Huh-7.5
infected cells
To test if BST-2 also restricts HCV release following infection, Huh-
7.5-BST-2 cells (open circles) or Huh-7.5 cells that did not express
BST-2 (closed circles) were infected with concentrated RLuc-HCV.
Infectivity release assays were performed by collecting supernatants
from infected cells at the indicated time points post-infection and re-
infecting new Huh-7.5 cells (Fig. 7A). Viral infectivity in Huh-7.5 was
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with an anti-BST-2 polyclonal antibody followed by staining with a secondary anti-rabbit Rhodamine antibody. For intracellular staining, cells were also permeabilized
before subjected to BST-2 staining (image c). Staining cells with DAPI veriﬁed nuclear imaging. Bright ﬁeld images that match to the same IFA images of Huh-7.5 (image d),
Huh-7.5-BST-2 cells (image e) and permeabilized Huh-7.5-BST-2 (image f) are also presented.
A. Dafa-Berger et al. / Virology 428 (2012) 98–111 103monitored 72 h post-infection by measuring luciferase-renilla activ-
ity. As these were release assays from HCV infected cells, the second
round of infection of Huh-7.5 cells resulted in lower viral luciferase
counts. These were approximately 2 log of magnitude lower in both
Huh-7.5-BST-2 and Huh-7.5 cells, compared to cells that were directly
electroporated with viral RNA and monitored for their luciferase
counts (compare to Fig. 6). Nevertheless, the overall release of HCV
particles from infected Huh-7.5-BST-2 cells was lower when com-
pared to virus that was released from Huh-7.5 infected cells that did
not express BST-2 (Fig. 7A). At 28 h post-infection, a 6-fold differencewas observed in viral release from Huh-7.5 cells that did not express
BST-2, compared to release from Huh-7.5-BST-2 stable cells. At later
time points post-infection, differences in HCV release from infected
cells were also observed and were 3–3.8-fold at respectively 72 h and
50 h post-infection in favor for Huh-7.5 that did not express BST-2
(Fig. 7A). In addition, effects of BST-2 on viral production associated
within cells were also compared between Huh-7.5-BST-2 and Huh-
7.5 cells. (Fig. 7B). Huh-7.5 (closed circles) or Huh-7.5-BST-2 stable
cells (open circles) were infected with concentrated RLuc-HCV and at
the indicated time points cells were harvested and analyzed for viral
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Fig. 5. HCV cannot modulate the expression of stably expressed BST-2. (A) Analysis of BST-2 expression in Huh-7.5-BST-2 cells following HCV infection: Huh-7.5-BST-2 cells
were infected with RLuc-HCV. 48 h and 72 h post-infection, cells were lysed and subjected to FACS analysis for BST-2 expression (lanes 3–4; black bars). Huh-7.5 cells that
did not express BST-2 (lane 1; white bar) and Huh-7.5-BST-2 that were not infected with HCV (lane 2; gray bar) were also analyzed for BST-2 expression. MFI values are
representative of the mean values of triplicate experiments; error bars show the standard deviation of the means. (B) Analysis of BST-2 expression in Huh-7.5-BST-2 cells
following HCV infection: Huh-7.5-BST-2 were either remained non-infected (lanes 2–5) or were infected with HCV (lanes 6–8). Cells were harvested at the indicated time
points post-viral infection and subjected to western blot analysis for BST-2 expression. Huh-7.5 cells were also stained for basal BST-2 expression (lane 1). Equal levels of
protein were loaded on the gel as shown by the expression of b actin (lower panel). (C) HCV replication in Huh-7.5-BST-2 stable cells: Huh-7.5-BST-2 cells (white bars) and
Huh-7.5 cells (black bars) were infected with RLuc-HCV and at the indicated time post-infection were lysed and subjected to renilla-luciferase measurements. RLU were
normalized to ensure equal protein levels that were subjected to the renilla-luciferase assay. Results are representative of the mean values of triplicate wells; error bars
show the standard deviation of the means. (D) FACS analysis of efﬁcient HCV replication in Huh-BST-2 stable cells: Huh-7.5-BST-2 cells were infected with RLuc-HCV and 72 h
post-infection cells were analyzed by FACS for both BST-2 and HCV NS5A expression. Cells were initially incubated with the primary polyclonal BST-2 and mouse NS5A
antibodies, followed by staining with anti-rabbit-Rhodamine Red-X and anti-mouse FITC conjugated antibodies. (E) Immunoﬂuorescence analysis of HCV infected Huh-7.5-
BST-2 cells: Huh-7.5-BST-2 cells were seeded on cover slips and were further infected with RLuc-HCV. 48 h post-infection cells were permeabilized and stained for both
BST-2 and HCV-NS5A using the appropriate antibodies (image b). Image a corresponds to a matched bright-ﬁeld image.
A. Dafa-Berger et al. / Virology 428 (2012) 98–111104yields associated within cells. As early as 30 h post-infection, a 2.7-
fold lower viral yields were detected within Huh-7.5-BST-2 stable
infected cells, compared with viral yields in Huh-7.5 infected cells. At
later time points of 50 h and 72 h post-viral infection, relativedifferences in cell associated viral production between the two cell
types were stabilized at 2-fold in favor of Huh-7.5 cells that did not
express BST-2 (Fig. 7B). Effects of BST-2 on HCV viral production and
release were also analyzed by real time PCR analysis, monitoring HCV
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A. Dafa-Berger et al. / Virology 428 (2012) 98–111 105RNA levels following infection of Huh-7.5 or Huh-7.5-BST-2. In Huh-
7.5-BST-2 cells that, both intracellular and secreted viral RNA levels
were relatively lower compared to RNA levels produced or secreted
from Huh-7.5 cells (Fig. 1; supplementary results). We conclude that
BST-2 moderately restricts HCV production following infection.
BST-2 inhibits HIV-delta Vpu release from Huh-7.5 cells
As BST-2 restriction on HCV release was marginal, its func-
tional activity in restricting HIV release from Huh-7.5-BST-2
stable cells was veriﬁed. Wild type and delta-Vpu HIVNL4.3
proviruses were produced in Huh-7.5 cells or in Huh-7.5-BST-2
stable cells and 48 h post-transfection supernatants containing
virus were used for infectivity assays of reporter TZM-bl cells, as a
measurement for particle release (Fig. 8). Effects of HIV vpu were
also monitored by expression of vpu in Huh 7.5 and Huh-7.5-BST-
2 cells (1 mg). As shown, wild-type HIV was efﬁciently released
from both Huh-7.5 (black bars) and Huh-7.5-BST-2 (white bars).
The release of HIV-delta Vpu particles from Huh-7.5 cells, where
BST-2 expression levels were moderately low, was also efﬁcient
and at similar levels as the wild type virus. However, the release
of HIV-delta Vpu virus from Huh-7.5-BST-2 was substantially
inhibited. Over expression of HIV Vpu had no effects on the
release of wild-type HIV from both Huh-7.5 and Huh-7.5-BST-2
cells. Importantly, HIV Vpu rescued the release of the delta-Vpu
HIV from Huh-7.5-BST-2 stable cells, conﬁrming its ability to
antagonize BST-2 activity in Huh-7.5 cells. Wild-type or delta-Vpu
proviruses producing cells were also analyzed by western
blot analysis for expression of CA-p24 (Serotec), to verify equal
levels of cell associated HIV particles that were produced (Fig. 8;
lower panel). Vpu expression was also validated by western blot
analysis using anti Vpu polyclonal antibody. Western blot analy-
sis for b-actin conﬁrmed equal protein levels that were loaded on
the gel. We conclude that in Huh-7.5 cell, stably expressed BST-2
is functional and efﬁciently restricts HIV-delta Vpu release. More-
over, the Vpu antagonizes the inhibitory effects of BST-2 and
rescues HIV-delta Vpu release from Huh-7.5-BST-2 cells.
HIV Vpu partially overcomes BST-2 mediated restriction of HCV
HIV-1 Vpu is known to antagonize the restriction function of
BST-2 and promotes HIV particle release presumably via down
regulation of surface expression of BST-2. The effects of over
expressed Vpu on BST-2 expression in Huh-7.5-BST-2 cells and on
Fig. 8. BST-2 is restricts the release of HIV-delta Vpu from Huh-7.5-BST-2 cells.
Huh-7.5 (black bars) or Huh-7.5-BST-2 (white bars) were transfected with HIVNL4.3
or HIVNL4.3 -delta Vpu provirus expression plasmids using lipofectamine 2000. To
assess effects of Vpu on BST-2-mediated restriction of HIV release, cells were also
co-transfected with each of the provirus DNA and with HIV Vpu (1 mg). 48 h post-
transfection, HIV containing supernatant was harvested, ﬁltered and was used for
infectivity assays to monitor HIV release. TZM-bl reporter cells were infected with
HIVNL4.3 or HIVNL4.3 -delta Vpu viruses that were produced in either Huh-7.5 or
Huh-7.5-BST-2 in the presence or absence of Vpu. 48 h post-infection cells were
analyzed for their b-gal activity as a measure for released HIV. Experiments were
presented as viral infectivity relative to wild-type HIV produced in Huh-7.5 cells
and were representative of mean values of triplicate wells; error bars show the
standard deviation of the means. To ensure equal levels of produced viruses, levels
of p24-CA for HIVNL4.3 or HIVNL4.3 -delta Vpu were monitored by western blot
analysis. Vpu expression was also validated by western blot analysis using anti
Vpu polyclonal antibody, followed by anti-rabbit HRP conjugated secondary
antibody. b-actin western blot veriﬁed equal protein levels that were loaded on
the gel.
A. Dafa-Berger et al. / Virology 428 (2012) 98–111106the restriction of HCV release were also tested (Fig. 9). Huh-7.5-BST-
2 stable cells were transfected with increasing concentrations of
HIV-1 Vpu (5–10 mg) and 48 h post-transfection cells were sub-
jected to FACS analysis to monitor both Vpu (white bars) and BST-2
expression levels (black bars). Over expression of Vpu in Huh-7.5-
BST-2 cells led to a relatively minor down regulation of BST-2
surface expression. Depending on the Vpu concentration that was
transfected into Huh-7.5-BST-2 cells, a low 1.8–2.7-fold decrease in
BST-2 surface expression was observed in cells that over-expressed
Vpu, compared to BST-2 expression levels in Huh-7.5-;BST-2 cells
that did not express Vpu (Fig. 9A; compare lanes 1 to lanes 2 and 3).
HCV production was also measured in Huh-7.5-BST-2 cells that over
expressed HIV Vpu (Fig. 9B). Huh-7.5-BST cells were co-electro-
porated with RLuc-HCV RNA and HIV Vpu expression plasmid
(10 mg). Viral production was measured 48 h post-electroporation
by harvesting cells and measuring their luciferase-renilla activity
(Fig. 9B). A relatively low (2-fold) decrease of HCV production was
observed in Huh-7.5-BST-2, compared to Huh-7.5 infected cells
(Fig. 9B, compare gray bar to black bar). Over expression of Vpu,
led to a 1.3-fold small increase in HCV production associated with
Huh-7.5-BST-2, but not to the same levels as detected in cells that
did not express BST-2 (Fig. 9B, compare gray bar at lane 1 to white
bar at lane 3). We conclude that over-expressed Vpu negligibleyrescues HCV production in Huh-7.5-BST-2 cells. Infectivity assays
were also performed, monitoring viral release from Huh-7.5-BST-2
stable cells that co-expressed HIV-1 Vpu. Huh-7.5-BST-2 stable cells
were electroporated with HCV RNA and Vpu expression vector.
Supernatant was collected 2 day post-electroporation and was used
to infect Huh-7.5 cells (Fig. 9C). A 1.85-fold decrease in release of
HCV form Huh-7.5-BST-2 cells was observed (black bar; lane 2),
compared to released particles from infected Huh-7.5 cells that did
not express BST-2 (gray bar: lane 1). HCV particle release was
slightly rescued (1.4-fold) upon over expression of Vpu (Fig. 9C;
white bar). Lower panel presented levels of Vpu expression as
measured by western blot using anti Vpu antibody. Overall, we
conclude that Vpu slightly antagonizes the function of BST-2 on viral
production and release by moderately modulating the surface
expression of BST-2. To verify that the observed moderate rescue
effects of HIV vpu on HCV replication and release are statistically
signiﬁcant, we performed a statistical analysis and determined the
p values of the above experiments (Fig. 9). Indeed, the p value for all
of the experiments were below 0.05, implying that in Huh-7.5 cells,
vpu moderately counteracts the inhibition effects of BST-2 on HCV
replication and release.Discussion
The establishment of in vitro tissue culture systems for
production of infectious HCV greatly enhanced the understanding
of the complete viral life cycle and the interactions with its host
(Murray and Rice, 2011). While much progress has been made at
characterizing early steps of viral entry and replication, insights
onto late steps of HCV assembly and release are less understood.
Moreover, host factors that regulate viral release are poorly
deﬁned (Jones and McLauchlan, 2010).
Persistence of HCV is established by evading the innate immune
response and attenuating the production of IFN Stimulated Genes
(ISGs). Despite that, the expression of numerous ISGs is elevated
upon HCV infection. However, little is known about their antiviral
activity (Haller et al., 2006; Horner and Gale, 2009; Sen and Sarkar,
2007; Sklan et al., 2009). In a search for novel ISGs that act against
important RNA viruses like HCV, Schoggins et al. analyzed the
antiviral activity of a wide range of ISGs and demonstrated that
different viruses are targeted by different sets of ISGs. Each virus is
susceptible to multiple antiviral genes, which together encompass
a range of inhibitory functions. RIG-I, MDA-5, IRF1 and IRF7 ISGs
possess anti-HCV activity and stimulate the expression of other
ISGs that limit HCV replication (Schoggins et al., 2011). Yet, while
more than 380 ISGs were screened, the described platform used a
lentiviral vector to express the different ISGs, thus, could not
identify those that were previously reported to restrict HIV
replication. Several restriction factors like TRIM5a, APOBEC3G
and BST-2/Tetherin, ﬁt this group and were probably selected
against in this speciﬁc assay.
In this report, the ability of human BST-2/Tetherin to modulate
HCV production and release was investigated. BST-2 was initially
recognized as a host factor that restricts the release of HIV-1 from
infected cells. Since then it has emerged as an inhibitor of viral
release of other enveloped viruses (Martin-Serrano and Neil, 2011).
However, its role in modulating HCV release has thus far not been
thoroughly studied. HCV is believed to bud into the ER and is then
released through the host TGN secretory pathway, where BST-2 is
enriched (Andrew et al., 2011; Dube et al., 2009; Hauser et al.,
2010; Masuyama et al., 2009). Several reports showed that HCV
replication occurs in detergent-insoluble sub-cellular domains or
lipid rafts membrane web structures that serve as a scaffold for
viral replication (Aizaki et al., 2004). As BST-2 also partially resides
in these micro-domains (Kupzig et al., 2003), we investigated its
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Fig. 9. HIV Vpu partially overcomes the restriction of BST-2 on HCV production and release. (A) Over expression of HIV Vpu moderately down regulates BST-2 expression in
Huh-7.5-BST-2 cells: Huh-7.5-BST-2 were electroporated with increasing concentrations of pDNA3.1-Vpu plasmid (5 and 10 mg). 48 h post-electroporation, cells were
analyzed for surface expression of BST-2 by FACS analysis (black bars). Vpu expression was also monitored by FACS, staining the cells with an anti Vpu polyclonal antibody,
followed by staining with a FITC conjugated anti rabbit secondary antibody (white bars). Results are representative of the mean values of triplicate wells; error bars show
the standard deviation of the means. (B) HIV Vpu moderately overcomes the restriction of BST-2 on HCV production in Huh-7.5-BST-2: Huh-7.5 and Huh-7.5-BST-2 cells were
co-electroporated with RLuc-HCV RNA and with pDNA3.1-HIV Vpu expression plasmid. 72 h post-electroporation, cells were harvested and their renilla-luciferase activity
was measured. RLU were normalized to ensure equal protein levels that were subjected to the renilla-luciferase assay. Results are representative of the mean values of
triplicate wells; error bars show the standard deviation of the means. (C). HIV-Vpu moderately overcomes the restriction of BST-2 on HCV release from Huh-7.5-BST-2: Huh-7.5
(gray bar) and Huh-7.5-BST-2 (white bar) cells were electroporated with RLuc-HCV RNA. Huh-7.5-BST-2 were also co-electroporated with RLuc-HCV RNA and with
pCDNA3.1-Vpu expression plasmid (10 mg; white bar). At 72 h post-electroporation cell supernatants were collected and used to infect new Huh-7.5 cells. 72 h post-
infection cells were harvested and subjected to renilla-luciferase assay for viral release in Huh-7.5 cells. RLU were normalized to ensure equal protein levels that were
subjected to Renilla-luciferase assay. Results are representative of the mean values of triplicate wells; error bars show the standard deviation of the means. Western blot
analysis conﬁrmed Vpu expression in Huh-7.5-BST-2 that were also transfected with HIV Vpu.
A. Dafa-Berger et al. / Virology 428 (2012) 98–111 107role in restricting HCV production and release from Huh-7.5 cells.
We demonstrated that in Huh-7.5 hepatocytes, only low basal
expression levels of BST-2 were detected (Fig. 1). Indeed, a recent
report by Erickson et al. demonstrated relatively medium expres-
sion levels of BST-2 in liver tissue (Erikson et al., 2011). We further
showed that basal BST-2 expression levels in Huh-7.5 cells were
not modulated following infection of cells with HCV (Fig. 2).
Treatment of Huh-7.5 cells with IFNa led to increased levels of
BST-2 expression. Similarly, IFNa-induced expression of BST-2 was
also not altered following HCV infection (Fig. 3). This was not
surprising since HCV could not replicate in IFNatreated cells,
conﬁrming that HCV lacks mechanisms to modulate BST-2 expres-
sion that is IFNa induced. Moreover, expression of IFNa-induced
BST-2 remained unchanged when cells were ﬁrst infected with
HCV and then treated with IFNa (Fig. 3). In Huh-7.5 cells that
stably expressed BST-2 and were further sorted for high BST-2
expression to generate Huh-7.5-BST-2, expression levels of BST-2
were also not modulated upon HCV infection. These results
support the overall conclusion that HCV lacks mechanisms to
counteract BST-2 function (Figs. 4 and 5). Immunostaining analysis
conﬁrmed that BST-2 does not co-localize with HCV (Fig. 5E).
Nevertheless, the study herein demonstrated that stably
expressed BST-2 blocked the release of HCV particles from viralproducing Huh-7.5 cells, following electroporation of viral RNA, as
well as restricted HCV release from Huh-7.5 infected cells
(Figs. 6 and 7). Surprisingly, unlike the case of HIV where cell-
associated viral production is not disrupted, in HCV, moderate
inhibitory effects of BST-2 were also detected on virus production
associated within cells (Fig. 7). As HCV assembly takes place
inside cells, BST-2 may partially disrupt this step. Further experi-
ments should validate this hypothesis. Similar effects on intra-
cellular levels of BST-2 were documented for ﬁloviral VLP release
(Jouvenet et al., 2009). The reasons for not measuring dramatic
accumulation of cell-associated viral proteins are not clear, but it
may be that VLPs that are targeted by BST-2 are degraded at a
higher rate from their synthesis. Alternatively, it may simply be
the case that only a fraction of the viral proteins that are
synthesized are actually released as particles. Thus, the amount
of viral protein that is observed in cell lysates would be deter-
mined by its intrinsic turnover rate rather than particle release
versus retention (Jouvenet et al., 2009).
Our results only partially agree with a recent published paper
by Ye et al., who demonstrated that Tetherin/BST-2 has negligible
restriction activity on HCV (Ye et al., in press). Their work
measured effects of BST-2 on viral RNA synthesis and not on
overall viral protein particle release. Signiﬁcantly, in their
A. Dafa-Berger et al. / Virology 428 (2012) 98–111108experimental design, BST-2 was transiently expressed and, as
shown by their immuno-ﬂuorescence analysis, only a small
fraction of cells expressed BST-2. In such experimental settings,
effects of BST-2 on HCV release could not be measured properly,
as in cells that did not express BST-2, HCV release was not
restricted. In the current study, BST-2 was stably expressed in
Huh-7.5 cells, which were further sorted based on their high BST-
2 expression, to obtain Huh-7.5-BST-2 stable cells. In these cells,
we observed that BST-2 moderately inhibited HCV production and
release (Figs. 6 and 7). Despite the disagreements, both reports
concluded that in vitro, BST-2 holds minor effects and even has
negligible activity in inhibiting HCV release, while the virus could
not counteract BST-2 activity.
Current model for the antiviral activity of BST-2 implies that
inhibition of viral release is non-speciﬁc. BST-2 dimerizes on the cell
surface and facilitates physical tethering of viral particles on the
surface of infected cells. Thus, enveloped viruses that bud through
the plasma membrane have been placed under evolutionary pres-
sure to antagonize BST-2 activity. The fact that viral replication of
several viruses from different families code for BST-2 antagonists
with distinct mode of action to counteract BST-2 activity, points to
an important antiviral function for BST-2, which was conserved in
evolution (Erikson et al., 2011). For HCV, which does not bud via
plasma membrane, viral measurements that were required to over-
come BST-2 inhibition were not essential. Moreover, along its
evolutionary development, HCV acquired alternative strategies to
efﬁciently replicate in hepatocytes, mainly by disrupting the IFNa
pathway and suppressing ISGs expression. This turned HCV to be
less susceptible to anti-viral effects of BST-2, when compared to
other viruses like HIV. In this study we conﬁrmed that BST-2 is
functional in Huh-7.5 cells, as it efﬁciently restricted the release of
HIV-1 delta-Vpu from Huh-7.5-BST-2 cells as well as of HCV. Over
expression of HIV Vpu rescued HIV delta-Vpu release from Huh-7.5-
BST-2 (Fig. 8). Additionally, HIV Vpu, moderately overcame BST-2
mediated inhibition of HCV release, and slightly down-regulated the
surface expression of BST-2 (Fig. 9). Overall, we suspect that, the
in vitro moderate activity of BST-2 in down regulating HCV replica-
tion and release may imply that BST-2 inhibition of HCV replication
and release is not of high relevance in vivo, and it is unlikely to be
accountable as a major mechanism by which IFNa inhibits HCV
replication in vivo. Nevertheless, as BST-2 is expressed in lipids rafts
and ER membranes, where HCV replicates and buds, and its
expression levels are moderately high in vivo, the biological sig-
niﬁcance of BST-2 on HCV replication and release should be further
evaluated. BST-2 expression levels in locations where HCV replicates
or assembled should be monitored (Lopez et al., 2012). As IFNa still
remains the backbone of HCV therapy and the antiviral functions
and mechanisms of numerous ISGs are still incompletely under-
stood, the biological signiﬁcance of BST-2 needs further investiga-
tion in vivo as it may enhance our understanding of the late steps of
HCV life cycle and may lead to presently unforeseen antiviral
treatments.Materials and methods
Cells and viruses
Huh-7.5 HCV permissive cells lines were a kind gift of Dr Charles
Rice (Rockefeller University). Cells were cultured at 37 1C, 5% CO2 in
Dulbecco’s Modiﬁed Eagle Medium (DMEM, Invitrogen) containing
10% fetal bovine serum (FBS) and 1mM nonessential amino acids
(NEAA - Gibco). HEK293T cells were grown in similar condition with
no addition of NEAA. FL-J6/JFH-5.C19Rluc2AUbi (RLuc-HCV) is a
monocistronic, full-length HCV genome derived from the infectious
genotype 2a HCV genome J6/JFH1 as described previously(Lindenbach et al., 2005). RLuc-HCV encodes the ﬁrst 19 residues of
the HCV Core protein fused to the N terminus of the RLuc Renilla
luciferase gene. To allow removal of Rluc from the HCV polyprotein, a
17-residue fragment of the self-cleaving foot-and-mouth disease
virus 2A protein (2A) and the ubiquitin monomer (Ubi) were fused
to the C terminus of Rluc as described (Tscherne et al., 2006).
In vitro transcription, electroporation and infection
RNA in vitro transcription was performed as previously
described (Lindenbach et al., 2005). Brieﬂy, Xba-I linearized
DNA template of the RLuc-HCV plasmid was transcribed by using
T7 RiboMAX
TM
Express Large Scale RNA Production System (Pro-
mega) and the HCV-RNA was puriﬁed using the RNeasy Mini kit
(QIAGEN) with on-column DNase treatment.
Electroporation – Sub-conﬂuent Huh-7.5 cells were trypsinized,
harvested by centrifugation (500g for 5 min), washed twice, and re-
suspended in ice-cold phosphate-buffered saline (PBS; Biological
Industries) at 1.5107 cells/ml. RLuc-HCV RNA (5 mg) was mixed
with 0.4 ml of cells in a 0.4-cm gap corvette and immediately pulsed
once with 270 V using a Gene-Pulser Xcell
TM
Electroporation System
(BioRad). Electroporated cells were allowed to recover for 10 min at
room temperature prior to the addition of complete medium and
were then plated in a 150-mm diameter cell culture dish. After 96 h,
electroporated cells were trypsinized and re-plated in complete
medium. Virus stocks containing supernatant from re-plated cells
were then harvested for 4 additional days of growth. Viral stocks
were stored at 80 1C until use.
Generation of Huh-7.5-BST-2 stable cell line
The human-BST-2 gene was ampliﬁed by PCR and was further
sub-cloned into a lentiviral vector, which also expressed a puromycin
selective marker that was translated via an IRES sequence. VSV-G
pseudotyped lentiviral particles that expressed human BST-2 were
generated by co-transfection of HEK293T cells with HIV packaging
plasmids (Tat;Rev, vpu) and the BST-2 expression lentiviral vector.
48 h post-transfection, supernatant containing the CMV-BST-2-IRES-
puromycin lentivirus was collected, ﬁltered and used to infect Huh-
7.5 cells. Transduced cells were selected for two weeks in complete
media supplemented with 6 mg/ml puromycin. Expression of stable
of BST-2 was validated by western blot and FACS analysis using anti
BST-2 polyclonal antibody. Huh-7.5 cells that were expressing BST-2
were further sorted based on high expression of BST-2 to obtain
Huh-7.5-BST-2 stable cells.
HCV concentration
Supernatant of Huh-7.5 cells electroporated with HCV RNA was
collected at different time points and clariﬁed by centrifugation at
3000 rpm for 10min (4 1C). All batches containing the virus were
mixed and Polyethylene glycol (PEG - MW 10000) solution (pH-7.2)
was added at a ratio of 1:4 (PEG:Virus). The solution was incubated
overnight at 4 1C and at the next day was centrifuged at 2300 rpm for
45 min (4 1C). The supernatant was removed and the pellet contain-
ing the virus was resuspended in 1/100 of the original volume. Finally
the virus was aliquoted and stored at 80 1C.
Luciferase renilla assay
To harvest samples for luciferase assays, cells were washed
once with PBS and then were lysed with 100 ml of renilla lysis
buffer (Renilla Luciferase Dual Assay System; Promega). Lysates
were frozen at 80 1C and were then thawed and vortexed. 50 ml
of sample was mixed with luciferase assay substrate (Promega)
and their luciferase activity was measured, using a Turner Designs
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(RLU) values were normalized to the protein amount in each
sample by measuring protein concentration using the Thermo
Scientiﬁc Pierce BCA Protein Assay Kit.
FACS
To assess BST-2 expression, cells were trypsinized, washed
twice with PBS and were ﬁxed with PFA 2% at room temperature.
Cells were washed again and blocked for 1 h at room temperature
with 4% FCS. For premeabilization of cells, blocking solution was
supplemented with 0.05% Triton x100. Cells were then washed
and stained with anti-human polyclonal BST-2 antibody (NIH
#11721) for 30 min at 4 1C. Cells were then washed three times
with cold PBS and were further incubated with Rhodamine Red-
X-conjugated goat anti-rabbit (Jackson Immuno-Research Labora-
tories) for 30 min at 4 1C in darkness. The expression levels of
BST-2 were analyzed by a ﬂow cytometer FACSCalibur ﬂow
cytometer (Becton Dickinson, Mansﬁeld, MA). For validating
HCV replication, cells were also incubated with anti-NS5A mono-
clonal antibody, following by staining with anti-mouse-FITC
conjugated antibody (Invitrogen). Expression of HIV Vpu was also
analyzed by FACS, using anti Vpu polyclonal antibody.
Effects of HIV Vpu on the expression of BST-2 in Huh-7.5 cells
To analyze the ability of Vpu to down regulate BST-2 expres-
sion in Huh-7.5-BST-2, pCDNA3.1 Vpu was transfected into Huh-
7.5-BST-2 cells using lipofectamine 2000. 48 h post-transfection,
BST-2 expression levels were analyzed by FACS using rabbit BST-2
antibody and a secondary anti-rabbit Rhodamine Red-X. Vpu
expression was detected with an anti Vpu polyclonal antibody,
followed by staining of cells with a secondary rabbit FITC
conjugated antibody (in the case of FACS analysis) or a secondary
antibody that was HRP conjugated (for western blot analysis).
Release of HIV from Huh-7.5-BST-2 cells
To analyze the effects of BST-2 on the release of HIV and
HIV-delta Vpu from Huh-7.5-BST-2, 15 mg of wild type HIVNL4.3 or
HIVNL4.3-delta Vpu proviruses DNA plasmids were transfected
into Huh-7.5 or Huh-7.5-BST-2 using lipofectamine 2000. To
analyze the effect of Vpu, 2 mg of pCDNA 3.1-Vpu was also co
transfected (empty pCDNA 3.1 vector was transfected into cells
that did not expressed Vpu). Virus particles were harvested 48 h
post-transfection and were used to infect HeLa TZM-bl for b-Gal
activity as readout of HIV particle release. Vpu was also co-
transfected with the proviral DNA to analyze its ability to rescue
HIV-delta Vpu release from Huh-7.5-BST-2 cells.
Immunoﬂuorescence analysis
Cells were plated on sterile cover slips, which were coated
with collagen and plated in a 6 well plate. 48 h later, the cells
were gently washed with PBS and ﬁxed with PFA 2% at room
temperature. Cells were washed again and blocked for 1 h at
room temperature with 4% FCS, supplemented or not with 0.05%
Triton 100 for premeabilization. Cells were then washed and
stained with a polyclonal anti-human BST-2 for 30 min at room
temperature. After washing the cells with PBS, cells were incu-
bated with Rhodamine Red-X conjugated-secondary antibody
(Jackson Immuno-Research Lab) for 30 min in darkness at room
temperature. Finally, cells were washed 3 times with PBS and
then the cover slips were dried, mounted and let to dry for 24 h,
before analyzed by confocal microscopy. For analysis of HCV
infection, cells were permiabilized and also stained with amonoclonal NS5A antibody, followed by staining with anti mouse
FITC conjugated antibody (Invitrogen). Cells were washed and
mounted for ﬂuorescence microscopy. Images were acquired by
using Nikon inverted TI microscope (Nikon) with a X40 objective
and a cooled 14bit CCD camera (Coolsnap HQ2, Photometrix,
Tucson AZ), using NIS-elements software package (Nikon).
Western blotting analysis
For the analysis of BST-2 expression, cells were harvested and
washed twice with cold PBS. The ﬁnal cell pellet was re-suspended
in ice cold RIPA buffer containing protease inhibitors, incubated for
30 min on ice and centrifuged at 13,000g for 30 min at 4 1C. The
obtained supernatants were designated as the total cell lysates and
their protein concentrations were determined by Bio-Rad protein
assay using Dye Reagent (BioRad). Samples were subjected to
SDS-PAGE under reduced conditions and were then transferred onto
nitrocellulose membrane (Pall Corporation, Pensacola, FL, USA).
Blocked membranes were probed with polyclonal antibody against
the human BST-2 and with a secondary HRP-conjugated anti-rabbit
antibody (Jackson Immuno-Research Lab). Western blot for Vpu
were performed using an anti Vpu polyclonal antibody following by
probing the membrane with a secondary anti-rabbit HRP conjugated
antibody. CA-p24 expression was validated by western blot analysis
with a goat a-p24-HRP conjugated (Serotec). b-actin was monitored
with a monoclonal antibody (SIGMA). Finally, the immunoreactive
proteins were visualized using enhanced chemiluminescence (ECL,
Biological Industries).
Analysis of HCV production and viral release
For measuring HCV production, cells were electroporated with
viral RNA and at different time points post-electroporation, cells
were lysed and their luciferase activity was measured as described
by the manufacture (Promega). For analysis of HCV particle release
following transfection or infection, infectivity release assays were
performed. Supernatant from viral producing cells or infected cells
was collected at different time points, clariﬁed and used for
infection of new Huh-7.5 cells. Infected cells were further grown
for additional 72 h and were then harvested for measuring their
renilla-luciferase activity.Acknowledgments
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